0

531569

SANJIVIN

img img img img
No Data Available

SANJIVANI PARANTERAL LTD. Share Price Update

As of the latest trading session, SANJIVANI PARANTERAL LTD. share price is currently at ₹206.6, which is down by ₹-3.89 from its previous closing. Today, the stock has fluctuated between ₹202.30 and ₹223.40. Over the past year, SANJIVANI PARANTERAL LTD. has achieved a return of -29.52%. In the last month alone, the return has been 3.21%.

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

SANJIVANI PARANTERAL LTD. fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    253.80

  • P/E Ratio (TTM)

    34.68

  • Beta

    0.57

  • Book Value / share

    36.49

  • Return on equity

    10.15%

  • EPS (TTM)

    6.07

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    2.62

info icon alternate text

SANJIVANI PARANTERAL LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2025 (Values in Cr)
Revenue 20.86
Operating Expense 17.67
Net Profit 2.62
Net Profit Margin (%) 12.55
Earnings Per Share (EPS) 2.13
EBITDA 3.89
Effective Tax Rate (%) 24.92
Particulars SEP 2025 (Values in Cr)
Revenue 15.50
Operating Expense 13.47
Net Profit 1.64
Net Profit Margin (%) 10.58
Earnings Per Share (EPS) 1.33
EBITDA 2.40
Effective Tax Rate (%) 25.11
Particulars JUN 2025 (Values in Cr)
Revenue 17.89
Operating Expense 15.63
Net Profit 1.73
Net Profit Margin (%) 9.67
Earnings Per Share (EPS) 1.46
EBITDA 2.68
Effective Tax Rate (%) 24.78
Particulars MAR 2025 (Values in Cr)
Revenue 18.18
Operating Expense 15.94
Net Profit 2.19
Net Profit Margin (%) 12.04
Earnings Per Share (EPS) 1.84
EBITDA 3.04
Effective Tax Rate (%) 17.66
Particulars DEC 2024 (Values in Cr)
Revenue 17.35
Operating Expense 15.15
Net Profit 1.90
Net Profit Margin (%) 10.95
Earnings Per Share (EPS) 1.62
EBITDA 2.86
Effective Tax Rate (%) 24.30
Particulars MAR 2025 (Values in Cr)
Revenue 70.10
Operating Expense 60.95
Net Profit 8.10
Net Profit Margin (%) 11.55
Earnings Per Share (EPS) 6.89
EBITDA 11.56
Effective Tax Rate (%) 21.81
Particulars MAR 2024 (Values in Cr)
Revenue 54.41
Operating Expense 47.35
Net Profit 6.17
Net Profit Margin (%) 11.33
Earnings Per Share (EPS) 5.28
EBITDA 8.75
Effective Tax Rate (%) 18.62
Particulars MAR 2023 (Values in Cr)
Revenue 35.49
Operating Expense 31.09
Net Profit 4.51
Net Profit Margin (%) 12.70
Earnings Per Share (EPS) 4.51
EBITDA 6.19
Effective Tax Rate (%) 8.70
Particulars MAR 2022 (Values in Cr)
Revenue 30.61
Operating Expense 25.97
Net Profit 4.85
Net Profit Margin (%) 15.84
Earnings Per Share (EPS) 4.85
EBITDA 5.97
Effective Tax Rate (%) 0.61
Particulars MAR 2021 (Values in Cr)
Revenue 25.10
Operating Expense 23.95
Net Profit 1.42
Net Profit Margin (%) 5.65
Earnings Per Share (EPS) 1.67
EBITDA 2.40
Effective Tax Rate (%) -0.70
Particulars MAR 2025 (Values in Cr)
Book Value / Share 30.83
ROE % 10.14
ROCE % 12.91
Total Debt to Total Equity 0.14
EBITDA Margin 16.49
Particulars MAR 2024 (Values in Cr)
Book Value / Share 22.14
ROE % 7.83
ROCE % 9.77
Total Debt to Total Equity 0.03
EBITDA Margin 16.08
Particulars MAR 2025 (Values in Cr)
Book Value / Share 30.84
ROE % 10.15
ROCE % 13.11
Total Debt to Total Equity 0.10
EBITDA Margin 16.50
Particulars MAR 2024 (Values in Cr)
Book Value / Share 22.14
ROE % 9.29
ROCE % 11.43
Total Debt to Total Equity 0.14
EBITDA Margin 16.08
Particulars MAR 2023 (Values in Cr)
Book Value / Share -3.07
ROE % 8.35
ROCE % 9.05
Total Debt to Total Equity 0.00
EBITDA Margin 14.93
Particulars MAR 2022 (Values in Cr)
Book Value / Share -7.58
ROE % 12.85
ROCE % 7.94
Total Debt to Total Equity 0.00
EBITDA Margin 19.50
Particulars MAR 2021 (Values in Cr)
Book Value / Share -52.83
ROE % -10.37
ROCE % 4.51
Total Debt to Total Equity 0.00
EBITDA Margin 9.56
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.41
Total Assets 78.19
Total Liabilities 78.19
Total Equity 39.87
Share Outstanding 1
Price to Book Ratio 7.77
Return on Assets (%) 10.35
Return on Capital (%) 16.86
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 9.56
Total Assets 43.40
Total Liabilities 43.40
Total Equity 27.89
Share Outstanding 1
Price to Book Ratio 6.78
Return on Assets (%) 14.20
Return on Capital (%) 21.36
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1.56
Total Assets 64.99
Total Liabilities 64.99
Total Equity 38.00
Share Outstanding 1
Price to Book Ratio 7.77
Return on Assets (%) 12.46
Return on Capital (%) 18.57
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 9.56
Total Assets 43.40
Total Liabilities 43.40
Total Equity 27.89
Share Outstanding 1
Price to Book Ratio 6.78
Return on Assets (%) 14.20
Return on Capital (%) 21.36
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.30
Total Assets 21.00
Total Liabilities 21.00
Total Equity -3.07
Share Outstanding 0
Price to Book Ratio -13.50
Return on Assets (%) 21.47
Return on Capital (%) -781.08
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.33
Total Assets 18.29
Total Liabilities 18.29
Total Equity -7.58
Share Outstanding 0
Price to Book Ratio -8.64
Return on Assets (%) 26.48
Return on Capital (%) -304.94
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.17
Total Assets 19.27
Total Liabilities 19.27
Total Equity -44.89
Share Outstanding 0
Price to Book Ratio -0.21
Return on Assets (%) 7.36
Return on Capital (%) -47.46
Particulars MAR 2025 (Values in Cr)
Net Income 10.35
Cash from Operations 13.72
Cash from Investing -21.91
Cash from Financing 10.45
Net change in Cash 0.94
Free Cash Flow 44.07
Particulars MAR 2024 (Values in Cr)
Net Income 7.57
Cash from Operations -9.58
Cash from Investing -12.21
Cash from Financing 23.15
Net change in Cash 0.23
Free Cash Flow -6.28
Particulars MAR 2025 (Values in Cr)
Net Income 10.35
Cash from Operations 1.08
Cash from Investing -5.80
Cash from Financing 6.13
Net change in Cash 0.09
Free Cash Flow 12.32
Particulars MAR 2024 (Values in Cr)
Net Income 7.57
Cash from Operations -9.58
Cash from Investing -12.21
Cash from Financing 23.15
Net change in Cash 0.23
Free Cash Flow -6.28
Particulars MAR 2023 (Values in Cr)
Net Income 4.94
Cash from Operations 4.72
Cash from Investing -0.99
Cash from Financing -3.73
Net change in Cash -0.03
Free Cash Flow 5.82
Particulars MAR 2022 (Values in Cr)
Net Income 4.87
Cash from Operations 8.56
Cash from Investing -0.67
Cash from Financing -7.68
Net change in Cash 0.16
Free Cash Flow 9.25
Particulars MAR 2021 (Values in Cr)
Net Income 1.41
Cash from Operations 0.61
Cash from Investing -0.41
Cash from Financing -0.25
Net change in Cash -0.09
Free Cash Flow 1.05
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.58 12.37 1.48 219.02 23.12 / 52.00
BLISS GVS PHARMA LTD 217.80 20.82 2.03 2304.08 105.05 / 225.00
CIPLA LTD 1330.85 22.61 3.26 107503.49 1283.00 / 1672.20
FERMENTA BIOTECH LIMITED 310.90 10.34 2.34 915.01 219.00 / 399.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.58 23.24 3.98 219.02 23.12 / 52.00
AMRUTAJAN HEALTH LTD 632.15 31.61 5.34 1827.59 548.05 / 789.95
ASTRAZENECA PHARMA IND LT 8878.75 106.70 27.78 22196.88 6501.60 / 10653.05
BLISS GVS PHARMA LTD 217.80 29.67 2.08 2304.08 105.05 / 225.00

SANJIVANI PARANTERAL LTD. shareholding pattern

Holding

62.75%
31.2%
6.03%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

SANJIVANI PARANTERAL LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
206.60 -1.85 redarrow
red-green-graph indicator
12 Bearish
4 Bullish
  • 5 Days 199.90
  • 26 Days 193.60
  • 10 Days 193.70
  • 50 Days 199.00
  • 12 Days 192.60
  • 100 Days 207.50
  • 20 Days 192.30
  • 200 Days 218.80
209.83 PIVOT

First Support

190.67

First Resistance

229.67

Second Support

170.83

Second Resistance

248.83

Third Support

151.67

Third Resistance

268.67

RSI

60.89

ADX

46.15

MACD

-1.02

Williams % R

-27.21

Commodity Channel Index (CCI)

182.79

Date

2026-02-13

Week

4743.00

Same Day

8470.00

Month

4997.00

1 Year

0.57

3 Year

0.62

Over 1 Month

3.21%

down

Over 1 Year

-29.52%

down

Over 3 Months

4.20%

down

Over 3 Years

75.41%

down

Over 6 Months

-1.03%

down

Over 5 Years

81.28%

down

SANJIVANI PARANTERAL LTD. Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2025 0.5 Final 19 Sep 2025 Equity shares

Top Gainers

SANJIVANI PARANTERAL LTD. Share Price

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades. The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun.

Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry. The Company is involved in the manufacturing of pharmaceutical medicines. Its products includes oral solids, small volume parenteral and sterile powder formulations.

The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative. The installed capacities for its products will be, 150 lac pa each for liquid vials and powder vials and 73 lac pa for its ampoules, taking the total capacity to 375 lac pa. The company came out with a public issue in Jan.'96 to part-finance the project.

The promoters have received firm inquiries from reputed pharmaceutical companies like Merind, Lupin Laboratories and USV for the first year' production of liquid vials and ampules.

During the year 1999-2000, the company has tied-up with India's first ranked pharmaceutical giant Ranbaxy for manufacturing its products.

During 2009, the Company acquired a new pharmaceutical manufacturing plant in Uttarakhand.

The Company launched two strategic ventures SPL Infusion Pvt. Ltd. in Pune for intravenous (IV) fluids and Alevia Healthcare S.R.O. in Prague, Czech Republic. for nutraceuticals in FY 2024-25. The base business has expanded by launching 15 new formulations, bringing the bringing to approximately 160 products in 2025. The nutraceuticals manufacturing unit in Prague was commissioned in partnership with Alevia Healthcare S.R.O by entering the burgeoning European nutraceutical market, valued at over EUR 70 billion.

Parent organization Indian Private
NSE symbol [-]
Founded 1994
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Sanjivani Paranteral Ltd?

Answer Field

Sanjivani Paranteral Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 206.60 as on Feb 16 2026 03:29 PM.

What is the Market Cap of Sanjivani Paranteral Ltd Share?

Answer Field

The market cap of Sanjivani Paranteral Ltd for NSE ₹ 0.00 & for BSE ₹ 253.80 as on Feb 16 2026 03:29 PM.

What is the 52 Week High and Low of Sanjivani Paranteral Ltd?

Answer Field

The 52 Week High and Low of Sanjivani Paranteral Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 311.60 and ₹ 161.00.

What is 1 year return for Sanjivani Paranteral Ltd?

Answer Field

The 1 year returns on the stock has been -29.52%.

What is the P/E Ratio of Sanjivani Paranteral Ltd Share?

Answer Field

As on Feb 16 2026 03:29 PM the price-to-earnings (PE) ratio for Sanjivani Paranteral Ltd share is 34.68.

What is the PB ratio of Sanjivani Paranteral Ltd Share?

Answer Field

As on Feb 16 2026 03:29 PM, the price-to-book (PB) ratio for Sanjivani Paranteral Ltd share is 36.49.

How to Buy Sanjivani Paranteral Ltd Share?

Answer Field

You can trade in Sanjivani Paranteral Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Sanjivani Paranteral Ltd Share on Bajaj Broking App?

Answer Field

To buy Sanjivani Paranteral Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Sanjivani Paranteral Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59